RMTC issues guidelines on glaucine testing
« Return to News
Due to glaucine's presence in bedding, a horse could ingest shavings prior to a race that could potentially result in a laboratory finding. This potential for inadvertent exposure, as well as intentional exposure, indicates that the simple use of a screening limit alone would likely not be sufficient in controlling the substance. Therefore, the following testing recommendations were issued for glaucine:
- 500 picograms/milliliter interim screening limit;
- Penalties: above 500 picograms/milliliter and below 1 nanogram/milliliter – warning; above 1 nanogram/milliliter – Class B Penalty; and
-
Horsemen should consider removing horses from bulk shavings at 24 hours pre-race to avoid the possibility of a finding for glaucine.
"We are pleased to see another laboratory in our sport working to meet the RMTC Laboratory Accreditation standards for testing expertise and proficiency," said RMTC Chair Alex Waldrop. "We hope to see additional laboratories join the University of Illinois-Chicago within the year." "RMTC Accreditation ensures that laboratories can consistently and reliably detect a wide variety of substances at low concentrations, which is a key to providing a racing product in the U.S. that is safe and fair."
The board also The RMTC's Scientific Advisory Committee (SAC) reported on the results of a 2016 RMTC-conducted DMSO study funded by the American Association of Equine Practitioners (AAEP). It was requested that RMTC determine a withdrawal recommendation for intravenous use of medical grade DMSO. Various samples from 30 horses tested by practicing veterinarians in Kentucky, Florida and California were analyzed.
RMTC's guidance to trainers is as follows:
- At 24 hours post-administration, 30/30 horses exceeded the 10 micrograms/milliliter threshold
- At 48 hours post-administration, 30/30 horses were below the 10 micrograms/milliliter threshold
- The highest concentration observed at 48 hours was 1.02 micrograms/milliliter
- Other medications administered during the sampling time were banamine, phenylbutazone, furosemide, methocarbamol, dexamethasone, procaine penicillin, ponazuril, carbocaine and gentamicin
For additional information, visit the RMTC website atrmtcnet.com or contact Hallie Lewis, RMTC communications and development consultant, at (859) 224-2848. (RMTC)